EQUEST® Oral Gel is a parasiticide active against a wide range of internal parasites of horses, ponies, mares and foals. It contains moxidectin, a second generation macrocyclic lactone of the milbemycin family. Moxidectin paralyses and kills parasites by its effect on their nervous systems. Moxidectin is rapidly absorbed following oral dosing. It is distributed throughout the body tissue for a rapid effect on parasites and is retained in the body over a prolonged period, remaining active against small strongyles picked up by the horse after dosing.

EQUEST® Oral Gel is ideal for parasite control in horses, ponies, mares and foals:

  • Palatable gel formulation
  • Effective against gastro-intestinal roundworms and bots
  • Controls encysted inhibited and developing larval stages of small strongyles
  • Persistent action against small strongyles
  • 13 week dosing interval
  • Effective against benzimidazole resistant cyathostomes
Categories: , , , Brand:

Active Ingredients :

EQUEST® Oral Gel (each 14.8 g syringe contains 280.0 mg moxidectin) Contains: 18.92 mg/g moxidectin and 37.84 mg/g benzyl alcohol and 0.24 mg/g disodium edetate as preservatives.


EQUEST® Oral Gel controls the following parasites with one easy treatment: Large strongyles (redworms): Strongylus vulgaris (adults and arterial stages), Strongylus edentatus (adults and visceral stages), Triodontophorus brevicauda (adults), Triodontophorus serratus (adults), Triodontophorus tenuicollis (adults), Small strongyles (redworms) (adults and intraluminal larval stages): Cyathostomum spp., Cylicocyclus spp., Cylicostephanus spp., Cylicodontophorus spp., Gyalocephalus spp. EQUEST® Oral Gel is effective against (developing) intramucosal L4 stages of small strongyles. At eight weeks after treatment early (hypobiotic) EL3 stages of small strongyles are eliminated. EQUEST® Oral Gel  is effective against benzimidazole resistant strains of cyathostomes. Ascarids: Parascaris equorum (adult and larval stages) Pinworms: Oxyuris equi (adult and larval stages) Stomach worms: Trichostrongylus axei and Habronema muscae (adults) Intestinal threadworms: Strongyloides westeri (adults) Bots: L2 and L3 stages of Gasterophilus intestinalis and Gasterophilus nasalis. Persistent activity: EQUEST® Oral Gelhas a persistent effect in preventing infection by small strongyles for 2 weeks after dosing and suppresses the presence of small strongyle eggs in the dung for 90 days.

Dosage and administration: This syringe contains sufficient gel to treat one 700 kg horse at the recommended dose rate (0.4 mg moxidectin per kg bodyweight). Each graduation on the calibrated syringe delivers sufficient gel to treat 25 kg bodyweight. Use of a scale or weigh tape is recommended to ensure accurate dosing. To avoid overdosing, care should be taken to accurately dose foals, especially low bodyweight foals or young ponies.

Dosing Guideline: The persistent activity of EQUEST® Oral Gel and its effectiveness against inhibited and developing larvae in the intestinal mucosa enables a reduction in the dosing frequency in strategic parasite control programmes. The recommended dosing interval for the control of small strongyles is 13 weeks. Consult your veterinary adviser for the appropriate programme for your specific needs.



How to set the dose

  1. Since the dose is based on the weight of the animal, you need to use a scale or weight tape to find each animal’s weight before treating with EQUEST® Oral Gel. Once the weight is known, set the dose for each horse or pony.
  2. Hold the syringe with the capped end pointing to the left and so that you can see the weight measurements and tick marks (small black lines) as shown in the diagram below. Each tick mark relates to 25 kg of bodyweight.
  3. Turn the dial ring until the left side of the ring lines up with the weight of the animal. In the diagram below, the dial ring is set to dose a 400 kg animal.
  4. Ensure the animal’s mouth is empty. With your thumb on the plunger, insert the nozzle of the syringe into the horse’s mouth at the space between front and rear teeth, and make sure the tip of the syringe is over the back of the tongue.
  5. Deliver the dose of gel onto the back of the tongue by gently pushing the plunger until it stops.
  6.  Raise the horse’s head once dosing is completed to ensure the gel is swallowed.
  7.  If gel remains in the syringe once the full dose has been delivered, replace the barrel cap. Use within 6 months. Do not use after the expiry date shown on the label.
  8. EQUEST® Oral Gel is specially formulated to be easily expelled by the plunger. Once in the horse’s mouth, EQUEST® Oral Gel liquefies. This facilitates dosing and reduces the risk of rejection.



Horses must not be slaughtered for human consumption within 32 days of treatment. Do not administer to young foals less than 4 months of age.

EQUEST® Oral Gel has been formulated specifically for use in horses only. Dogs or cats may be adversely affected by the concentration of moxidectin in this product if they are allowed to ingest spilled gel or have access to used syringes.

Do not administer in case of known hypersensitivity to the active ingredient or to any other milbemycins and to any other ingredients of the veterinary medicinal product. Do not use the same syringe to treat more than one animal unless horses are running together or are in direct contact with each other on the same premises. Do not smoke, drink or eat while handling the product. The use of protective gloves is recommended. Wash hands or any exposed area after use. Avoid direct contact with skin and eyes. In the event of eye contact, flush the eye with copious amounts of clean water and seek medical advice. For animal treatment only. Keep out of the reach and sight of children.



EQUEST® Oral Gel is safe to use in foals over 4 months of age, mares, ponies and horses. Mares may be treated at any stage of pregnancy and lactation. Ataxia, depression, abdominal pain, muscle tremor, flaccid lower lip and swelling of the muzzle could be observed on very rare occasions. These adverse effects are usually transient and disappear spontaneously in most cases. Transient adverse reactions may occur at twice the recommended dose in foals and 3 times the recommended dose in adults. The signs are depression, inappetence, ataxia, and drooping lower lip 8 to 24 hours following dosing. Symptoms of moxidectin overdose are the same as those observed in very rare occasions at the recommended dosage. In addition, hypothermia may occur.

Symptomatic treatment is not generally necessary and recovery is generally complete within 24 to 72 hours. There is no specific antidote.


Pharmaceutical precautions:

After opening, use within 6 months. Do not store above 25°C. Keep the syringe in the carton. After first use record the date to be disposed on the label space provided.



High density polyethylene syringe containing 14.8 g of gel with a graduated plunger with a low density polyethylene piston and cap packed as follows:

  • Box containing one syringe.
  • Box containing 10 individually boxes syringes.
  • Box containing 20 syringes.